08:00 , Dec 15, 2014 |  BioCentury  |  Strategy

Momenta moving on

Data announced in October represent the first fruits of Momenta Pharmaceuticals Inc. 's novel drug pipeline, which will play a larger role in the company's strategy going forward as it steps back from complex generics....
07:00 , Aug 3, 2009 |  BioCentury  |  Product Development

Through a back door

Funxional Therapeutics Ltd. believes its small molecule broad-spectrum chemokine inhibitors can provide advantages over current treatments for inflammatory and autoimmune diseases. The first test for lead compound FX125L will be whether it can provide similar...
08:00 , Nov 13, 2008 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute myelogenous leukemia (AML) Chemokine (CXC motif) receptor 4 (CXCR4); chemokine (CXC motif) ligand 12 (stromal cell-derived factor 1) (CXCL12; SDF-1a)...
07:00 , Jun 26, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/ marker/pathway Summary Licensing status Publication and contact information Neurology Stroke Stromal cell-derived factor-1a (SDF-1a); CXC chemokine receptor 4 (CXCR4); cellular prion protein (PrPc) Studies in cell culture and rats...
07:00 , Jul 16, 2007 |  BioCentury  |  Product Development

Wounds: Not open & shut

The failure of a series of wound healing agents, combined with disappointing sales for the few products that were approved, eroded interest in the space in the 1990s. But efforts now have been rekindled by...
08:00 , Jan 26, 1998 |  BioCentury  |  Tools & Techniques

Made to order proteins

Companies with enabling technologies may have few opportunities to tout their wares, as researchers tend to report on their own results rather than on the underlying work that made their experiments possible. Thus when Stanford...